{"id":66746,"date":"2024-11-20T14:00:54","date_gmt":"2024-11-20T03:00:54","guid":{"rendered":"https:\/\/hudson.org.au?post_type=hdsn_news_post&p=66746"},"modified":"2025-01-16T11:40:10","modified_gmt":"2025-01-16T00:40:10","slug":"childhood-blood-cancer-new-treatment-approach","status":"publish","type":"hdsn_news_post","link":"https:\/\/hudson.org.au\/news\/childhood-blood-cancer-new-treatment-approach\/","title":{"rendered":"Childhood blood cancer: new treatment approach"},"content":{"rendered":"\n

Dr Catherine Carmichael<\/a> aims to identify the key mechanisms that drive development of an aggressive form of childhood blood cancer<\/a>, acute myeloid leukaemia (AML).<\/p>\n\n\n\n

\n
\n

At a glance<\/h2>\n

Dr Catherine Carmichael is investigating the key mechanisms underpinning the development, relapse and therapy resistance of childhood AML. She aims to develop innovative new models of childhood AML that recapitulate the human disease and can be used to gain an enhanced understanding of how this disease develops and how it can be stopped.<\/p>\n

The two types of experimental models that Dr Carmichael is developing will allow her team to develop new treatments for childhood AML with reduced toxicity, enhanced efficacy and increased likelihood of long-term remission and cure.<\/p>\n <\/div>\n <\/div>\n\n \n\n\n

Leukaemia is the most common form of cancer diagnosed in children and the second leading cause of cancer-related death in children.<\/strong><\/p>\n\n\n\n

About 40 per cent of children diagnosed with AML do not survive past five years, and many of those who do survive will suffer long-term side effects from the highly toxic treatment that cured their leukaemia.<\/p>\n\n\n\n

Side effects can include damage to the heart, brain and reproductive organs, as well as a higher rate of secondary cancers later in life.<\/p>\n\n\n\n

Dr Carmichael , Group Head Leukaemia Modelling and Therapeutic Discovery Research<\/a> and her team are working to develop non-chemotherapeutic and less toxic treatments, so these young people can make the most of their second chance at life.<\/p>\n\n\n\n

This all starts with a better understanding of how the childhood blood cancer develops and identifying key weaknesses that can be targeted with new therapies.<\/p>\n\n\n

\n
\"Dr<\/a>
Dr Catherine Carmichael<\/em><\/figcaption><\/figure>\n<\/div>\n\n\n

“Our overall aim is to identify new treatments for this aggressive disease, saving children from not just leukaemia, but the unwanted effects of current cancer therapy.”<\/em><\/strong> Dr Catherine Carmichael.<\/strong><\/p>\n\n\n\n

This is where the science gets really interesting, as Dr Carmichael explains: “Up to 80 per cent of childhood and infant AMLs are driven by large chromosomal abnormalities called gene fusions, which lead to the impaired activity of critical blood cell regulators.”<\/p>\n\n\n\n

“Targeting these gene fusions would be transformative for AML therapy, but currently most gene fusions remain undruggable. So, our research focuses instead on performing large-scale unbiased drug and genetic screens to identify unique druggable gene targets that AML cells depend on to survive,” she said.<\/p>\n\n\n\n

A major problem to overcome is the fact that AML cells derived from patients can only survive in the laboratory for a short period of time, so Dr Carmichael and her team are developing new approaches to generate renewable sources of AML cells for ongoing analysis in the laboratory.<\/p>\n\n\n\n

Stem cell innovation: creating renewable AML cells<\/h2>\n\n\n\n

The first approach they are using involves generating AML gene fusions within human blood stem cells and using these cells to induce AML in immunocompromised mice.<\/p>\n\n\n\n

The second approach involves using the Nobel Prize-winning induced pluripotent stem cell (iPSC) technology to reprogram AML cells from patients back into an immature stem cell-like state. These so-called AML-derived iPSCs can then be expanded indefinitely in the laboratory.<\/p>\n\n\n\n

Both approaches will provide Dr Carmichael and her team with a ready source of AML cells for large-scale experimental study and identification of new drug targets.<\/p>\n\n\n\n

Ultimately, Dr Carmichael’s team aims to develop new treatment options for childhood AML, which will be more effective and have reduced toxicity and long-term side effects.<\/p>\n\n\n\n

Dr Carmichael’s overall aim is to explore new potential treatments for this poor-outcome disease, saving countless children from not just leukaemia, but the unwanted acute and chronic effects of current cancer treatments.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

Blood cancer 101<\/h2>\n